ProfileGDS5678 / 1423878_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 78% 76% 78% 76% 78% 79% 80% 79% 77% 77% 77% 77% 78% 77% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.3021578
GSM967853U87-EV human glioblastoma xenograft - Control 25.1971576
GSM967854U87-EV human glioblastoma xenograft - Control 35.3187978
GSM967855U87-EV human glioblastoma xenograft - Control 45.2236776
GSM967856U87-EV human glioblastoma xenograft - Control 55.4422378
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.3163779
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.5706980
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.505279
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.2095577
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.2629977
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.2141677
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.3253677
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.3092278
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.1872377